For progressive keratoconus, only Avedro's corneal cross-linking procedure is FDA approved and widely covered by insurance.
In 2016, Avedro's corneal cross-linking procedure became the first and only FDA approved corneal cross-linking treatment for progressive keratoconus. Since then, the procedure has been completed more than 18,000 times at more than 300 practices nationwide.
Today, the treatment is widely covered by commercial insurance. Click here to view your insurance policy
Supported by the National Keratoconus Foundation, this safe, minimally invasive outpatient procedure works by stiffening the weakened cornea to slow or halt progression of the disease.
Make sure your cross-linking is FDA-approved and covered by insurance. Click here to find a cornea specialist near you
Approved uses
Photrexa Viscous® (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are used with the KXL®System in corneal cross-linking to treat eyes in which the cornea, the clear dome shaped surface that covers the front of the eye, has been weakened from the progression of the disease keratoconus or following refractive surgery, a method for correcting or improving your vision.
Tell your healthcare provider if you are pregnant or plan to become pregnant.
Important Safety Information
Ulcerative keratitis, a potentially serious eye infection, can occur. Your doctor should monitor defects in the outermost corneal layer of the eye for resolution.
The most common ocular side effect is haze. Other ocular side effects include inflammation,
fine white lines, dry eye, disruption of surface cells, eye pain, light sensitivity, reduced sharpness of vision, and blurred vision. The risk information provided here is not comprehensive. To learn more, talk to your healthcare provider.
Go to www.livingwithkeratoconus.com/ to obtain the FDA-approved product labeling.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
